MarketMoodz
LNTH — Lantheus Holdings, Inc.
Is LNTH overbought or oversold? Here is the current MarketMoodz read.
Lantheus Holdings, Inc. (LNTH) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $100.26. The rating moved from Neutral to Oversold on August 16, 2026.
- Public ratingOversold (as of August 19, 2026)
- Last close$100.26
- Last changeMoved from Neutral to Oversold on August 16, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
Lantheus Holdings, Inc. (LNTH) is well positioned to benefit from rising demand in diagnostics and radiopharmaceutical imaging tied to oncology screening and biologics commercialization. Near-term catalysts include broader adoption of population screening diagnostics and improved utilization of specialized manufacturing capacity. Headwinds include payer reimbursement pressures and regulatory or manufacturing risks that could delay revenue realization. Given current market tone, institutional flows, and sector-level tailwinds for diagnostics and CDMO activity, the company has reasonable upside potential over the next month assuming execution on commercialization and stable macro conditions.
Key factors
- Strengthening demand for diagnostics and population screening (oncology, CRC) increases addressable market for imaging agents and lab services that Lantheus supplies.
- Exposure to radiopharmaceuticals and specialized imaging products positions the company to benefit from biologics/oncology readthroughs and increased CDMO/CRO activity.
- Favorable near-term market tone (risk-on, earnings momentum) and steady institutional flows support equity performance in the healthcare/diagnostics segment.
- Product pipeline and commercial execution: recent commercial actions and potential new indications could drive revenue growth and better utilization of manufacturing capacity.
- Manageable operational leverage: modest upside to margins if volume growth and manufacturing utilization improve; potential for cash generation to fund growth or M&A.
- Limited negative social sentiment and lack of recent adverse filings in the available data set reduce short-term headline risk.
Risks
- Payer strategy and reimbursement pressure: heightened payer analytics and plan rationalization could compress pricing or limit coverage for certain imaging agents.
- Regulatory setbacks or slower-than-expected regulatory approvals for pipeline products, which would delay revenue catalysts.
- Competitive threats from larger diagnostics, radiopharma developers, and alternative imaging technologies that could erode market share.
- Manufacturing or supply-chain disruptions affecting radiopharmaceutical production and on-time deliveries to customers.
- Macro volatility or a reversal in risk-on sentiment tied to inflation data and geopolitical developments could weigh on the stock.
- Limited immediate financial disclosure context (no EDGAR comparison available) increases near-term uncertainty about leverage and cash runway assumptions.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for LNTH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.